Apart from clinically evaluated ovarian cancer biomarkers, promising preclinical studies are examining new biomarkers, such as integrins [56] and the gonadotropin-releasing hormone (GnRH) receptor [57], which are not only able to detect minuscule tumor deposits but are also uniformly expressed in many cancers, and thus widen the applicability of these imaging contrast agents. The gene discussed is GNRHR; the disease is neoplasm.